ArticleFrontiers in oncology2026
Prediction of tumor progression in intermediate and advanced hepatocellular carcinoma undergoing TACE combined with targeted immunotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter arterial chemoembolization (TACE) combined with targeted immunotherapy have become the standard first-line treatment strategy for intermediate and advanced hepatocellular carcinoma (HCC), but some patients still cannot benefit from this treatment. This study aimed to construct a prediction model based on a cohort of HCC patients to guide individualized treatment decisions. Methods: A total of 243 intermediate and advanced HCC patients who received TACE combined with targeted immunotherapy from January 1, 2019 to March 31, 2024 were retrospectively enrolled. The optimal prognostic factors were screened by Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression. A nomogram model for predicting the probability of radiologic progression-free survival at 6-, 12-, and 24-month was constructed based on the screened risk factors, and the model performance was evaluated by calibration curve, decision curve analysis, and restricted cubic spline analysis. Results: Multivariate COX analysis showed that total bilirubin, D-dimer (DD) and portal vein tumor thrombosis (PVTT) were independent risk factors affecting the tumor progression of patients. LASSO regression screened out 10 key prognostic factors: aspartate aminotransferase, total bilirubin, albumin (ALB), white blood cell count, DD, alpha-fetoprotein, CD4+ T cell count, PVTT, tumor number (≥3) and lymph node invasion. Compared with the Cox regression model, significant advantages in screening prognostic factors were demonstrated by the LASSO regression model. Therefore, the risk factors identified by LASSO regression were chosen to construct a nomogram prediction model for subsequent analysis. The model showed good discrimination ability (Log rank P<0.05), calibration ability and net benefit of clinical strategy in both the training and validation group. Restricted cubic spline analysis found that ALB level and DD were significantly nonlinearly correlated with patient prognosis. Conclusion: This study constructed a multidimensional prediction model for tumor progression in patients with intermediate and advanced HCC. It was helpful to screen the best benefit population and optimize the treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.